Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the use of CDK4/6 inhibitors with endocrine therapy in treating women with HR+ HER2- advanced breast cancer, but it reports no new clinical findings.

In this study, the researchers found that different CDK4/6 inhibitors used in treating HR+/HER2- advanced breast cancer have varying safety profiles and impacts on patient quality of life.

This study conducted in an Iraqi oncology setting found generic Palbociclib to have a safety profile consistent with previous data, with observed side effects including high rates of neutropenia and anemia, particularly among patients receiving it with Fulvestrant.

This study observed that dalpiciclib is associated with fewer adverse events like diarrhea and hepatotoxicity compared to other CDK4/6 inhibitors, potentially offering better patient-perceived safety and quality of life.

This meta-analysis found that in postmenopausal women with a history of breast cancer, 8 weeks of vaginal estrogen therapy while on aromatase inhibitors did not result in systemic absorption of sex hormones, suggesting potential safety for treating vulvovaginal atrophy in this context.

This study found that in estrogen receptor-positive breast cancer cells, 17β-estradiol repressed polyamine oxidase transcription by interacting with AP-1 sites on its promoter.

This article reviews the skin condition myxedema associated with hypothyroidism, highlighting its characteristic non-pitting, glycosaminoglycan-rich nature, and reports no new results.

This review found that fulvestrant is well tolerated in postmenopausal women with hormone receptor-positive advanced breast cancer, showing lower incidence of joint disorders than non-steroidal aromatase inhibitors.

This clinical study observed that in patients with advanced breast cancer and BRCA1/2 mutations, talazoparib provided significantly better progression-free survival, objective response, clinical benefit, and patient-reported outcomes compared to physician’s choice chemotherapy, despite common side effects like anemia and fatigue.

This study observed that aromatase inhibitors caused hair loss in menopausal women with breast cancer, mimicking male pattern baldness rather than female androgenetic alopecia.

This study reports that health-related quality of life was generally maintained, and sometimes improved, in patients with HR+/HER2- advanced or metastatic breast cancer treated with palbociclib, compared to monotherapy, across various study types.

This review highlights the possible impact of side effects from endocrine therapy on quality of life, emphasizing that these can lead to poor adherence and early treatment discontinuation in patients with hormone receptor positive early breast cancer, potentially worsening survival outcomes.

This review summarizes evidence and adverse event management recommendations for Sacituzumab Govitecan in metastatic triple-negative breast cancer and hormone receptor-positive breast cancer, emphasizing favorable survival data from clinical trials.

This review describes oncotherapy-induced alopecia in patients receiving hormone therapy for hormone-receptor-positive breast cancer and concludes that topical hormones should not be used due to oncogenic potential.

This study concluded that while CDK4/6 inhibitors, used to treat HR+ HER2- metastatic breast cancer, generally did not worsen health-related quality of life, they were associated with increased patient-reported issues like diarrhea and hair loss upset.

An 86-year-old man with prostate cancer was diagnosed with a rare, low-grade breast cancer and underwent surgery but declined additional hormone therapy.

This case report describes successful treatment with low-dose oral minoxidil for endocrine therapy-induced alopecia in a breast cancer patient unresponsive to topical minoxidil.

This paper discusses the role of steroid sulfatase in hormone-dependent tumors and highlights the development of potent inhibitors, noting the commencement of a phase I trial for one inhibitor in postmenopausal breast cancer patients.

This case report describes a woman with hypertension, alopecia, and other symptoms, revealing that her condition was due to ovarian hyperthecosis, highlighting the overlap of adrenal and ovarian disorders.

In this study, researchers found that the thyroxine receptor agonist TDM10842 accelerated the onset of anagen, a hair growth phase, in C3H mice, potentially through activation of the Wnt/beta-catenin and Hedgehog pathways, with Pclaf playing a key role in this process.

This study found that in female androgenetic alopecia, androgen receptors are highly positive in affected areas, supporting their role as regulators of genetically predisposed hair follicles despite normal serum hormone levels.

This report describes a case of meningioma in a transwoman treated long-term with estradiol and cyproterone acetate, suggesting possible concern over female sex steroids and meningioma risk.

This retrospective study observed that breast cancer treatments disrupted normal blood counts and led to bone marrow suppression, highlighting the need for nutritional counseling to improve patient quality of life.

This study found that male pattern baldness may serve as a clinical marker for circulating sex hormone levels in men with localized prostate cancer, while chest hair density showed no significant hormone association.

This study found that thyroid-stimulating hormone receptors are functionally expressed in various skin cells, implying potential physiological and pathological roles in skin, especially in conditions like autoimmune diseases.

This study observed that deslorelin acetate implants reduced sexual activity and improved coat quality in a German Spitz dog with alopecia X, suggesting its potential as a less invasive and reversible treatment for managing reproductive function and this dermatopathy.

This review discusses the role of various hormones in diffuse hair loss and emphasizes the need for further research to clarify their complex interactions and potential therapeutic implications, but reports no new clinical results.

This study concludes that hormone therapy can significantly improve skin hydration, elasticity, thickness, and reduce wrinkles by modulating various skin cells through estrogen receptors.

This study found that systemic testosterone exposure in transgender individuals with XX genotype alters skin biology, increasing androgen and estrogen receptor-positive cells, collagen density, and fibronectin expression while reducing immune cells, which could affect surgical outcomes by promoting a male skin phenotype.